Enzastaurin, an inhibitor of PKCβ, enhances antiangiogenic effects and cytotoxicity of radiation against endothelial cells

Translational Oncology

Volumn 1, Issue 4, 2008, Pages 195-201

  Spalding, Aaron C ^a   Zeitlin, Benjamin D ^b   Wilder Romans, Kari ^a   Davis, Mary E ^a   Nor, Jacques E ^b   Lawrence, Theodore S ^a   Ben Josef, Edgar ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953752349     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08151     Document Type: Article

References (39)

1. Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, et al. (1999). Protein kinase C lies on thesignaling pathway for vascular endothelial growth factor-mediated tumor developmentand angiogenesis. Cancer Res 59, 4413-4418.
2. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, and Mills GB (2002). Convergence ofmultiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediatedphosphorylation and inactivation by lysophosphatidic acid through a proteinkinase C-dependent intracellular pathway. Mol Cell Biol 22, 2099-2110.
3. Goode N, Hughes K, Woodgett JR, and Parker PJ (1992). Differential regulationof glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267, 16878-16882.
4. Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, Schubiger PA, Bodis S, and Pruschy M (2001). The phosphatidylinositide 3′-kinase/Aktsurvival pathway is a target for the anticancer and radiosensitizing agent PKC412,an inhibitor of protein kinase C. Cancer Res 61, 8203-8210.
5. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, et al. (1999). Prognostic significanceof angiogenesis in human pancreatic cancer. Br J Cancer 79, 1553-1563.
6. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, and Yamazaki Y (2001). Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expressionin stromal cells and intratumoral microvessel density as independent predictorsof overall and relapse-free survival. Cancer 92, 1788-1797.
7. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, and Vierra M (2000). Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48, 919-922.
8. Evans JD, Cornford PA, Dodson A, Neoptolemos JP, and Foster CS (2003).Expression patterns of protein kinase C isoenzymes are characteristically modulatedin chronic pancreatitis and pancreatic cancer. Am J Clin Pathol 119, 392-402.
9. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, and Teicher BA (2004). LY317615 decreases plasma VEGF levels inhuman tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53, 133-140.
10. Tabatabai G, Frank B, Wick A, Lemke D, von Kurthy G, Obermuller U, Heckl S, Christ G, Weller M, and Wick W (2007). Synergistic antiglioma activity ofradiotherapy and enzastaurin. Ann Neurol 61, 153-161.
11. Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, and Ben-Josef E (2007). Inhibition of protein kinase C{beta} by enzastaurin enhances radiationcytotoxicity in pancreatic cancer. Clin Cancer Res 13, 6827-6833.
12. Rademaker-Lakhai J, Beereport L, Witteveen EO, Radema SA, Visseren-Grul CM, Musib LC, Van Hal G, Beijnen JH, Schellens JHM, and Voest EE (2004). Phase Iand pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin. 2004ASCO Annual Meeting.
13. Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, Shyr Y, Wu H, and Hallahan DE (2006). SRC family kinase inhibitor SU6656 enhances antiangiogeniceffect of irradiation. Int J Radiat Oncol Biol Phys 64, 1197-1203.
14. Fertil B, Dertinger H, Courdi A, and Malaise EP (1984).Mean inactivation dose:a useful concept for intercomparison of human cell survival curves. Radiat Res 99,73-84.
15. Nor JE, Christensen J, Mooney DJ, and Polverini PJ (1999). Vascular endothelialgrowth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelialcell survival and induction of Bcl-2 expression. Am J Pathol 154, 375-384.
16. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, et al. (2005). The protein kinase Cbetaselectiveinhibitor, Enzastaurin (LY317615.HCl), suppresses signaling throughthe AKT pathway, induces apoptosis, and suppresses growth of human coloncancer and glioblastoma xenografts. Cancer Res 65, 7462-7469.
17. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, andHittelman W (1999). Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59, 107-114.
18. Tan J, Geng L, Yazlovitskaya EM, and Hallahan DE (2006). Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiatedvascular endothelium. Cancer Res 66, 2320-2327.
19. Yan W, Bentley B, and Shao R (2008). Distinct angiogenic mediators are requiredfor basic fibroblast growth factor and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumorangiogenesis. Mol Biol Cell 19, 2278-2288.
20. Hata Y, Rook SL, and Aiello LP (1999). Basic fibroblast growth factor inducesexpression of VEGF receptor KDR through a protein kinase C and p44/p42mitogen-activated protein kinase-dependent pathway. Diabetes 48, 1145-1155.
21. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R, and Imamura M (1998). Expression of two angiogenicfactors, vascular endothelial growth factor and platelet-derived endothelial cellgrowth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34, 1439-1447.
22. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, and Kore M (1997). Enhanced expression of vascular endothelial growth factor in humanpancreatic cancer correlates with local disease progression. Clin Cancer Res 3,1309-1316.
23. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, and Post S (2002). High expression of vascular endothelial growthfactor predicts early recurrence and poor prognosis after curative resection forductal adenocarcinoma of the pancreas. Pancreas 25, 122-129.
24. Wang Q, Zhou Y, and Evers BM (2006). Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells. Neoplasia 8,781-787.
25. Li H and Weinstein IB (2006). Protein kinase C beta enhances growth and expressionof cyclin D1 in human breast cancer cells. Cancer Res 66, 11399-11408.
26. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, Quintas J, Kufe DW, and Weichselbaum RR (1997). Decreasing the apoptoticthreshold of tumor cells through protein kinase C inhibition and sphingomyelinaseactivation increases tumor killing by ionizing radiation. Cancer Res 57, 4340-4347.
27. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, et al. (1999). Blockage of thevascular endothelial growth factor stress response increases the antitumor effectsof ionizing radiation. Cancer Res 59, 3374-3378.
28. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, et al. (1998). Combined effectsof angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287-291.
29. Ning S, Laird D, Cherrington JM, and Knox SJ (2002). The antiangiogenicagents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157, 45-51.
30. Thornton SC, Walsh BJ, Bennett S, Robbins JM, Foulcher E, Morgan GW, Penny R, and Breit SN (1996). Both in vitro and in vivo irradiation are associatedwith induction of macrophage-derived fibroblast growth factors. Clin Exp Immunol 103, 67-73.
31. Houchen CW, George RJ, Sturmoski MA, and Cohn SM (1999). FGF-2 enhancesintestinal stem cell survival and its expression is induced after radiationinjury. Am J Physiol 276, G249-G258.
32. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D, and Jain RK (2000). Tumor oxygenation in hormone-dependenttumors during vascular endothelial growth factor receptor-2 blockade, hormoneablation, and chemotherapy. Cancer Res 60, 4556-4560.
33. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, and King GL (1996). Characterization of vascular endothelialgrowth factor's effect on the activation of protein kinase C, its isoforms, and endothelialcell growth. J Clin Invest 98, 2018-2026.
34. Takahashi T, Ueno H, and Shibuya M (1999). VEGF activates protein kinaseC-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNAsynthesis in primary endothelial cells. Oncogene 18, 2221-2230.
35. Buchler P, Reber HA, Buchler MW, Friess H, and Hines OJ (2002). VEGF-RIIinfluences the prognosis of pancreatic cancer. Ann Surg 236, 738-749; discussion749.
36. von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schimer M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B, et al. (2000). De novoexpression of vascular endothelial growth factor in human pancreatic cancer: evidencefor an autocrine mitogenic loop. Gastroenterology 119, 1358-1372.
37. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, Somcio R, Liu W, Evans DB, Wu Y, Hicklin DJ, et al. (2005). Vascular endothelial growth factorreceptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104, 427-438.
38. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, et al. (2006). Vascular endothelial growth factor receptor-1activation mediates epithelial to mesenchymal transition in human pancreaticcarcinoma cells. Cancer Res 66, 46-51.
39. Goekjian PG and Jirousek MR (2001). Protein kinase C inhibitors as novelanticancer drugs. Expert Opin Investig Drugs 10, 2117-2140.